Read about the promise of cellular therapies and our work in Breakthrough
We are excited to host an outstanding panel of speakers on precision cellular immunotherapies and CAR-Tregs at The American College of Rheumatology Symposium at FOCIS 2023!
Upcoming T-cell therapies may treat antiphospholipid syndrome and other autoimmune diseases without compromising a patient’s defenses against infection.
We introduce CATCR-T cells, a novel engineered T cell receptor technology to selectively target autoreactive B cells that drive autoimmune diseases (Plenary Session III, November 14, 2022).
A novel targeted immunotherapy approach developed by researchers at the Ludwig Center, the Lustgarten Laboratory, and Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center employs new antibodies against genetically altered proteins to target cancers.
Researchers developed a prototype for a new cancer immunotherapy that uses engineered T cells to target a genetic alteration common among all cancers.
The benefit of alpha blockers may extend to other respiratory infection. Read more in eLife.
Retrospective data from the United States Department of Veterans Affairs suggests benefit of inhibiting catecholamine-mediated cytokine dysregulation to prevent severe COVID-19
Researchers at Johns Hopkins are racing to understand the connection between SARS-CoV-2 and a deadly immune system malfunction called a cytokine storm.
Read more on Johns Hopkins News
Read our interview on Healio Rheumatology
A pathogen linked to periodontal disease might trigger production of autoantigens that set off and sustain inflammatory immune responses in the joints in rheumatoid arthritis (RA).
Researchers from Johns Hopkins Medicine have narrowed down the link between chronic gum disease and rheumatoid arthritis, identifying the common bacterium at play in both conditions.
